It is necessary to review the recently developed and biological mechanism progress of menin–MLL1 interaction molecular inhibitors, which might offer possibilities for the more in-depth development of menin–MLL1 interaction-based molecular inhibitors in treating cancer and MLL-r leukemia. The gene discussed is KMT2A; the disease is cancer.